Rosetta Genomics Ltd. has received regulatory approval for their diagnostic test using MicroRNA technology to differentiate between squamous and non-squamous non-small cell lung cancer (NSCLC).
At present, the test is approved for clinical use by the New York State Department of Health Clinical Laboratory Evaluation Program and is expected to become available nationwide at the end of 2008. The diagnostic test utilizes a tumor tissue sample for MicroRNA testing with a sensitivity and specificity of over 90% for identification of squamous cell NSCLC.
© 1998-2007 OncoEd.com All Rights Reserved.
These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.
Patient Home
